2024-11-01 - Analysis Report
## Pfizer Inc. (PFE) Stock Analysis

**1. Performance Comparison:**

Pfizer Inc. (PFE) is a pharmaceutical company that develops and manufactures medicines and vaccines. 

PFE has underperformed the S&P 500 (VOO) significantly, with a cumulative return of -13.51% compared to the S&P 500's 131.38%. This represents a substantial underperformance of -144.89%, placing it at the 3.05% percentile of its historical performance relative to the S&P 500.

**2. Recent Price Movement:**

* Closing Price: $28.3 (Last-market: $28.29)
* 5-day Moving Average: $28.52
* 20-day Moving Average: $29.01
* 60-day Moving Average: $28.99

The stock price is currently below its 5-day, 20-day, and 60-day moving averages, suggesting a short-term downtrend. However, the price is relatively close to its longer-term averages, indicating potential for recovery.

**3. Technical Indicators:**

* **RSI:** 35.76 -  Indicates that the stock is currently in oversold territory, potentially suggesting a bounce back.
* **PPO:** -0.29 - A negative PPO value indicates a bearish trend, which aligns with the recent price movement.
* **Delta_Previous_Relative_Divergence:** 1.78 (+) - A positive value suggests a short-term uptrend, hinting at potential upward momentum.
* **Expected Return:** 0.0% - This indicates that over a long-term horizon (2 years or more), PFE is expected to provide similar returns to the S&P 500.

**4. Recent Earnings and Outlook:**

| Date | EPS | Expected EPS |
|---|---|---|
| 2024-10-29 | 1.06 | 0.614 |
| 2024-07-30 | 0.6 | 0.458 |
| 2024-05-01 | 0.82 | 0.516 |
| 2024-01-30 | 0.1 | -0.19 |
| 2023-10-31 | -0.17 | -0.32 |

The most recent earnings for the quarter ending October 29, 2024, came in at $1.06, exceeding the expected EPS of $0.614. This indicates a positive surprise and suggests that the company is performing well. However, a complete analysis of the earnings report is required to assess the company's overall financial health and future prospects.

**5. Financial Information:**

**1) Revenue and Profitability:**

| Quarter | Revenue | Profit Margin |
|---|---|---|
| 2024-06-30 | $13.28B | 75.16% |
| 2024-03-31 | $14.88B | 77.29% |
| 2023-12-31 | $14.25B | 46.92% |
| 2023-09-30 | $13.23B | 29.95% |
| 2023-06-30 | $13.01B | 75.11% |

Pfizer has consistently generated strong revenue, with a significant increase in the first two quarters of 2024. However, the profitability has been volatile, indicating potential challenges in maintaining high margins.

**2) Capital and Profitability:**

| Quarter | Equity | ROE |
|---|---|---|
| 2024-06-30 | $87.70B | 0.05% |
| 2024-03-31 | $92.28B | 3.38% |
| 2023-12-31 | $89.01B | -3.78% |
| 2023-09-30 | $96.93B | -2.46% |
| 2023-06-30 | $99.02B | 2.35% |

The company's equity has remained relatively stable, but the return on equity (ROE) has been volatile, showing periods of both profitability and losses. This suggests potential challenges in efficiently utilizing its capital.

**6. News and Recent Issues:**

* **Recent Earnings News:**  Detailed analysis of recent earnings news from sources like Shacknews will provide valuable insights into the company's performance and future outlook. 
* **Recent Market Outlook:** Analyze recent market trends and sentiment surrounding PFE, taking into account relevant news, industry developments, and analyst opinions. 
* **Analyst Opinions and Performance Highlights:** Gather insights from analysts on PFE's performance, potential risks, and growth prospects. Sources like Finbold can provide valuable insights.

**7. Overall Analysis:**

PFE currently faces a challenging environment, marked by underperformance relative to the S&P 500. The stock is in oversold territory, indicating a potential for recovery, but the negative PPO suggests a bearish trend. While the recent earnings beat expectations, further analysis is required to assess the long-term outlook. The company's financial performance exhibits some volatility, highlighting potential challenges in maintaining profitability and efficient capital utilization. 

**Conclusion:**

PFE remains a complex investment, with both potential upside and downside risks. Thoroughly analyzing recent earnings, market outlook, and analyst opinions will be crucial in making informed investment decisions.  While the stock's oversold status suggests a potential rebound, the company's past performance and current challenges require careful consideration. 
